Influence of angiotensin on the early progression of heart failure.
The purpose of this study was to elucidate the role of circulating ANG II in mediating changes in systemic and renal hemodynamics, salt and water balance, and neurohormonal activation during the early progression of heart failure. This objective was achieved by subjecting six dogs to 14 days of rapid ventricular pacing (240 beats/min) while fixing plasma ANG II concentration (by infusion of captopril + ANG II) either at approximately normal (days 1-8, 13-14) or at high physiological (days 9-12) levels. Salt and water retention occurred during the initial days of pacing before sodium and fluid balance was achieved by day 8. At this time, cardiac output and mean arterial pressure were reduced to approximately 55 and 75% of control, respectively; compared with cardiac output, reductions in renal blood flow were less pronounced. Although plasma ANG II concentration was maintained at approximately normal levels, there were sustained elevations in total peripheral resistance (to approximately 135% of control), filtration fraction (to approximately 118% of control), and plasma norepinephrine concentration (to 2-3 times control). During the subsequent high rate of ANG II infusion on days 9-12, there were no additional sustained long-term changes in either systemic or renal hemodynamics other than a further rise in right atrial pressure. However, high plasma levels of ANG II induced sustained antinatriuretic, sympathoexcitatory, and dipsogenic responses. Because these same long-term changes occur in association with activation of the renin-angiotensin system during the natural evolution of this disease, these results suggest that increased plasma levels of ANG II play a critical role in the spontaneous transition from compensated to decompensated heart failure.
Lohmeier
T E
TE
University of Mississippi Medical Center, Department of Physiology and Biophysics, Jackson, Mississippi 39216-4505, USA. tlohmeier@physiology.umsmed.edu
Mizelle
H L
HL
Reinhart
G A
GA
Montani
J P
JP
D000804:Angiotensin II / Q000494:pharmacology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D001798:Blood Proteins / Q000032:analysis; D002216:Captopril / Q000494:pharmacology; D002303:Cardiac Output, Low / Q000503:physiopathology*; D002304:Cardiac Pacing, Artificial; D018450:Disease Progression; D004285:Dogs; D004573:Electrolytes / Q000097:blood; D006400:Hematocrit; D006439:Hemodynamics / Q000187:drug effects; D008297:Male; D018377:Neurotransmitter Agents / Q000097:blood; D012079:Renal Circulation / Q000187:drug effects; D012965:Sodium Chloride / Q000378:metabolism; D014882:Water-Electrolyte Balance
D000806:Angiotensin-Converting Enzyme Inhibitors; D001798:Blood Proteins; D004573:Electrolytes; D018377:Neurotransmitter Agents; D000804:Angiotensin II; D012965:Sodium Chloride; D002216:Captopril